News Orexo AB

Stocks

ORX

SE0000736415

Pharmaceuticals

Market Closed - Nasdaq Stockholm 12:00:00 2026-11-13 EST			5-day change	1st Jan Change
0.8770 ^SEK	+1.27%		-35.89%	-97.09%

11-13	Orexo presents new data for OX640, showing rapid absorption and high stability	FW
11-12	Seven stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW

All News

Mentions Relevance

ecaca9044c3892c8831a50548c0488f6.n4Jp72vBenmyDQPCVx_7-l8nNDvbEQn1Bbi6J74ZZ_g.7sQKpTGpGyn_IGy2Z1yQkhRmZVWOZluab9eKRIxKKJ_p9yCrKqUQHflqWg

11-13	Orexo presents new data for OX640, showing rapid absorption and high stability	FW
11-13	Orexo : New OX640 Data Presented at ACAAI Demonstrate Rapid Achievement of Clinically Meaningful Epinephrine Levels and Enhanced Stability	PU
11-11	Orexo, SVF Vaccines to Explore Powder-Based LNP-mRNA Vaccine Formulations	MT
11-11	Orexo : and SVF Vaccines collaborate to explore AmorphOX formulation of LNP-mRNA Vaccines	PU
11-11	Orexo launches research collaboration with SVF Vaccines on mRNA vaccines	FW
11-11	Orexo : publishes disclosure document regarding rights issue	PU
11-10	Orexo : to present additional data on OX640, a novel nasal epinephrine powder, in two oral presentations at ACAAI 2026	PU
11-10	Orexo presents new OX640 data at US medical congress	FW
11-09	Orexo trades today on Nasdaq Stockholm ex-rights in rights issue	FW
11-05	Orexo : ORXOY - Books will close at the close of business, November 5, 2026.	PU
11-03	Orexo sets terms for previously announced rights issue	FW
10-29	Orexo: FDA accepts resubmitted application for IZIPRY - decision expected in March 2027	FW
10-29	Orexo announces that the FDA has accepted the resubmitted marketing application for IZIPRY for review	FW
10-29	Orexo AB Announces FDA Acceptance Of IZIPRY NDA Resubmission For Review	CI
10-23	Orexo - CEO interview with Nikolaj Sørensen about latest quarterly report	FW
10-22	Orexo AB, Nine Months 2026 Earnings Call, Oct 22, 2026
10-22	Orexo AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
10-22	Orexo's operating loss widened, CEO highlights progress in development pipeline and expects lower costs	FW
10-14	Orexo reports promising results for oral semaglutide tablet	FW
10-14	Orexo : reports encouraging bioavailability in first in vivo study of oral semaglutide formulation based on AmorphOX	PU
10-14	Orexo AB (Publ.) Reports Promising Initial Results from First Preclinical Pharmacokinetic in Vivo Study of Oral Semaglutide Tablet Based on Amorphox® Technology	CI
10-06	CEO interview with Nikolaj Sørensen at Orexo ahead of the upcoming offering	FW
10-06	Orexo: Withdrawing fair value range	AQ
10-06	Orexo Plans SEK250 Million Rights Issue to Fund Drug Development	MT
10-06	Orexo seeks to raise SEK 250m in offering	FW